A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting
Open Access
- 26 January 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (1) , e0170305
Abstract
Cells of the innate and adaptive immune system are key factors in the progression of atherosclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute atherothrombotic events such as coronary artery disease, cerebrovascular disease and peripheral arterial disease. Here, we describe the cloning, expression, purification, and immunoreactivity assessment of a recombinant single-chain variable fragment (scFv) derived from a human anti-αIIbβ3 antibody (HuAb) selected to target atheromatous lesions for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to play a role in inflammation, in platelet-leucocyte aggregates and in thrombi formation and might thus be considered relevant biomarkers of atherosclerotic progression. The DNA sequence that encodes the anti-αIIbβ3 TEG4 scFv previously obtained from a phage-display selection on activated platelets, was inserted into the eukaryote vector (pPICZαA) in fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experiments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L culture). The advantage of P. pastoris as an expression system is the production and secretion of recombinant proteins in the supernatant, ruling out the difficulties encountered when scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity). The improved conditions allowed for the recovery of highly purified and biologically active scFv fragments ready to be grafted in a site-directed way to nanoparticles for the imaging of atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.Keywords
Funding Information
- French National Research Agency Program (ANR-07-PCVI-0023 ANR-13-BSV5-0018)
- SFR TecSan (Technology for Health) (University of Bordeaux)
- French National Research Agency (ANR-10-LABX-57)
This publication has 38 references indexed in Scilit:
- BAFF Receptor mAb Treatment Ameliorates Development and Progression of Atherosclerosis in Hyperlipidemic ApoE−/− MicePLOS ONE, 2013
- Expression of Recombinant AntibodiesFrontiers in Immunology, 2013
- scFv Antibody: Principles and Clinical ApplicationJournal of Immunology Research, 2012
- Non-invasive imaging of atherosclerosisEuropean Heart Journal - Cardiovascular Imaging, 2012
- Depletion of B2 but Not B1a B Cells in BAFF Receptor-Deficient ApoE−/− Mice Attenuates Atherosclerosis by Potently Ameliorating Arterial InflammationPLOS ONE, 2012
- Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosisBlood, 2010
- Oxidized LDL-Activated Platelets Induce Vascular InflammationSeminars in Thrombosis and Hemostasis, 2010
- Antigen-Driven Evolution of B Lymphocytes in Coronary Atherosclerotic PlaquesThe Journal of Immunology, 2009
- Characterisation, cloning and sequencing of a conformation-dependent monoclonal antibody to the α IIb β 3 integrin: interest for use in thrombus detectionPlatelets, 2001
- Very high expression of an anti-carcinoembryonic antigen single chain Fv antibody fragment in the yeast Pichia pastorisJournal of Biotechnology, 2000